Biomea Fusion is trading 5.7% lower at $1.41 as investors await BMF-650 Phase I topline results, delayed to October 2026. - Results were previously expected in the third quarter. - The public offering was terminated, and no securities were sold. - Shares fell despite broader U.S. indexes trading higher on September 25, 2026.